Received Jun 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | P2443 | — |
Late second dose /first shot of Twinrix in November 2024 and today the second dose was given; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 64-year-old male patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Previously administered products included Twinrix (received first dose in November 2024.). On 02-JUN-2025, the patient received the 2nd dose of Twinrix. On 02-JUN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose /first shot of Twinrix in November 2024 and today the second dose was given ). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JUN-2025 The pharmacist called regarding a patient who had received the first shot of Twinrix in November 2024 and today the second dose was given which led to drug dose administration interval too long. The pharmacist asked information about the recommended interval between the delayed second dose and the third dose.